Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States

According to research presented during the 2024 American Society of Hematology Annual Meeting, real-world data on the use of tafasitamab for patients with relapsed/refractory DLBCL support the clinical benefit of this drug, with a real-world PFS of 11.3 months (95% CI: 9.8-13.6) and real-world OS of 24.8 months (95% CI: 17.8-not evaluable). Multivariable analysis from this trial also suggests that greater benefit may be achieved when tafasitamab is used in earlier lines vs. later lines of treatment.